Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 5:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 55 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: ORA, Inc. Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease

NCT03598699
View directory record Official record
Conditions
Dry Eye
Interventions
AXR-159, Vehicle
Drug
Lead sponsor
AxeroVision, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Andover, Massachusetts • Raynham, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Food Allergy Diagnostic Test Response to Previous Oral Challenge Response

NCT03693456
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Conjunctival Allergen Challenge
Other
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.

NCT03990051
View directory record Official record
Conditions
Chronic Ocular Graft-versus-host Disease
Interventions
Pro-ocular™ topical gel, Placebo topical gel
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome

NCT04206020
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sun City West, Arizona • Andover, Massachusetts • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 2 Interventional

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

NCT01275105
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis

NCT03320434
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
PRT-2761 0.5%, PRT-2761 1%, Patanol, Pred-forte, PRT-2761 0%
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.

NCT02039765
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine tartrate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

NCT02756624
View directory record Official record
Conditions
Healthy Subjects
Interventions
AC-170 0.24%, AC-170 Vehicle
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 2 Interventional

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

NCT05759208
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OK-101, Placebo
Drug
Lead sponsor
Okyo Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
6
States / cities
Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 4 Interventional

A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome

NCT02139033
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Retaine™
Drug
Lead sponsor
Ocusoft, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers

NCT01853722
View directory record Official record
Conditions
Ocular Infection
Interventions
DCN01, Unisol
Drug
Lead sponsor
Deacon Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 6, 2026, 5:00 PM EDT
Not listed Phase 3 Interventional

A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

NCT06329791
View directory record Official record
Conditions
Dry Eye Disease
Interventions
AZR-MD-001, Vehicle
Drug · Other
Lead sponsor
Azura Ophthalmics
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Chandler, Arizona • Glendale, California • Newport Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye

NCT05411367
View directory record Official record
Conditions
Dry Eye Disease
Interventions
SI-614, Placebo
Drug
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Not applicable Interventional

A Prospective Clinical Study to Evaluate the Repeatability of the Visibly Vision Test

NCT06812572
View directory record Official record
Conditions
Myopia, Astigmatism
Interventions
Visibly Vision Test
Device
Lead sponsor
Visibly
Industry
Eligibility
22 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Harlingen, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Study of ST-100 as Treatment for Dry Eye Disease

NCT05241470
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ST-100 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Stuart Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Andover, Massachusetts • Raynham, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

NCT04268069
View directory record Official record
Conditions
Dry Eye Disease
Interventions
PL9643 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Andover, Massachusetts • Raynham, Massachusetts • Shelby, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 6, 2026, 5:00 PM EDT
Completed No phase listed Observational

Effect of Controlled Adverse Environment (CAE) on Tear Film Stability

NCT01547936
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model

NCT01730872
View directory record Official record
Conditions
Chronic Allergic Conjunctivitis
Interventions
Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 1 Interventional

A Study of AG-80308 in Dry Eye Patients

NCT05372107
View directory record Official record
Conditions
Dry Eye Disease
Interventions
AG-80308
Drug
Lead sponsor
Allgenesis Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Newport Beach, California • Raynham, Massachusetts • Clinton, Utah
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 6, 2026, 5:00 PM EDT
Terminated Phase 1 Interventional

Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections

NCT03038971
View directory record Official record
Conditions
Allergic Conjunctivitis, Allergic Rhinitis
Interventions
Dose Level 1, Dose Level 2, Placebo
Biological
Lead sponsor
Woodmont Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

NCT00689078
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 1%, Prednisolone Acetate 0.12%, Loteprednol Etabonate 0.2%, Placebo
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 6, 2026, 5:00 PM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of Ketorolac and HPMC to Treat Dry Eye

NCT03693183
View directory record Official record
Conditions
Dry Eye
Interventions
Ketorolac/HPMC, HPMC, Vehicle
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 6, 2026, 5:00 PM EDT
Completed Not applicable Interventional

Product Preference With Systane Compared to Artificial Tears on Frequency of Drop Use

NCT00347984
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Lubricant eye drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Oct 6, 2026, 5:00 PM EDT
Recruiting Not applicable Interventional

Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

NCT05438732
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy
Interventions
smaller incision, new generation implantable miniature telescope (SING-IMT)
Device
Lead sponsor
VisionCare, Inc.
Industry
Eligibility
65 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Loma Linda, California • Long Beach, California • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 6, 2026, 5:00 PM EDT